Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688444 | PMC |
| http://dx.doi.org/10.1016/j.ihj.2015.08.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aspiration thrombectomy of the hepatic veins in Budd Chiari Syndrome.
Acta Gastroenterol Belg
January 2025
Department of Radiology, Antwerp University Hospital, Antwerp, Belgium.
Article Synopsis
- Budd-Chiari syndrome (BCS) is a rare, serious condition caused by blocked blood flow from the liver due to clotting.
- Treatment usually requires long-term blood thinners and methods to unblock the veins.
- This case report presents a new technique called hepatic venous thromboaspiration, which is used to help reopen the obstructed veins.
Extensive Deep Vein Thrombosis in a Young Man Taking Tirzepatide for Weight Loss.
AACE Clin Case Rep
September 2024
Department of Internal Medicine, College of Medicine & Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
Background/objective: Obesity and rapid weight loss are risk factors for developing deep vein thromboses (DVTs). Our aims were to present a patient who developed extensive DVT after relatively rapid and severe weight loss that followed taking tirzepatide and to raise the awareness among health care professionals regarding the risk of DVT that can be associated with significant weight loss due to these agents.
Case Report: We present the case of a 20-year-old young man, with raised body mass index of >35 kg/m, who was initiated on tirzepatide treatment for weight loss, with 12-kg weight lost over 6 weeks.
Molecular Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: A Clinical Update from a Basic Research Perspective.
Adv Respir Med
November 2024
Laboratory of Immunometabolism, Research Division, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City 06720, Mexico.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but severe condition characterized by persistent obstruction and vascular remodeling in the pulmonary arteries following an acute pulmonary embolism (APE). Although APE is a significant risk factor, up to 25% of CTEPH cases occur without a history of APE or deep vein thrombosis, complicating the understanding of its pathogenesis. Herein, we carried out a narrative review discussing the mechanisms involved in CTEPH development, including fibrotic thrombus formation, pulmonary vascular remodeling, and abnormal angiogenesis, leading to elevated pulmonary vascular resistance and right heart failure.
View Article and Find Full Text PDFThe Enigma of Retroperitoneal Fibrosis: Clinical Implications and Diagnostic and Therapeutic Challenges.
Cureus
November 2024
Department of Internal Medicine/Rheumatology, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso, USA.
Retroperitoneal fibrosis (RPF) is a rare disease with a nonspecific presentation. RPF can be classified into Idiopathic, the most common, or secondary due to malignancy and various medications resulting in chronic inflammation and fibrosis in the retroperitoneum. The complications arise due to the compression of structures in the retroperitoneum.
View Article and Find Full Text PDFEfficacy and safety of a dedicated venous stent for the treatment of iliofemoral venous obstruction: A single center experience.
Vascular
December 2024
Department of Vascular Surgery, Xiamen Branch of Zhongshan Hospital, Fudan University, Xiamen, China.
Background: Endovascular recanalization with venous stenting is the preferred treatment for iliofemoral venous obstruction. We reviewed our institutional experience and mid-term outcomes with endovascular therapy for iliofemoral venous obstruction using the Venovo Self-expanding Venous Stent (BARD Peripheral Vascular, Inc., Tempe, AZ, USA).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!